Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial is a research paper published in Neuro-Oncology (2021). On theSindex it has a DataRank of 2.4. It has been cited 110 times, with 96 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.706
From this paper's citation signal
Citation Network Contribution
1.7
From 74 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 96 citers.
Ziopharm Oncology, Inc
Grant: 2P01CA163205
Ziopharm Oncology, Inc
Grant: CA069246-20
NINDS NIH HHS
Grant: K08 NS101091
NCI NIH HHS
Grant: P01 CA069246
NINDS NIH HHS
Grant: R01 NS116144
NCI NIH HHS
Grant: P01 CA163205
National Institutes of Health
Grant: 3P01CA163205-03S1
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas
National Institutes of Health
Grant: 3P01CA069246-03S1
OPTIMIZATION OF CYTOCHROME P450
National Institutes of Health
Grant: 5P50CA221747-02
SPORE for Translational Approaches to Brain Cancer
National Institutes of Health
FWCI
7.92
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment
Additional file 1 of Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment